Assembly Biosciences, Inc. (ASMB) has a negative trailing P/E of -54.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -1.83%.
Criteria proven by this page:
Overall SharesGrow Score: 59/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -5.7 | -0.14 | 3.14 | 0.00 | - |
| 2017 | -22.5 | 3.62 | 8.52 | 106.87 | - |
| 2018 | -6.8 | -0.10 | 2.94 | 41.81 | - |
| 2019 | -8.8 | 0.29 | 3.15 | 53.95 | - |
| 2020 | -4.6 | 0.10 | 1.20 | 3.64 | - |
| 2021 | -0.8 | -0.01 | 0.60 | 16.12 | - |
| 2022 | -0.7 | 0.02 | 0.76 | 0.00 | - |
| 2023 | -0.7 | 0.02 | 1.10 | 6.29 | - |
| 2024 | -2.4 | 0.05 | 2.84 | 3.32 | - |
| 2025 | -62.3 | 0.68 | 1.84 | 5.27 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.57 | $0.00 | $-44.26M | - |
| 2017 | $-2.41 | $9.02M | $-42.81M | -474.7% |
| 2018 | $-3.98 | $14.8M | $-90.75M | -613% |
| 2019 | $-2.78 | $15.96M | $-97.63M | -611.6% |
| 2020 | $-1.50 | $79.11M | $-59.53M | -75.3% |
| 2021 | $-2.77 | $6.25M | $-129.86M | -2076.4% |
| 2022 | $-22.82 | $0.00 | $-92.07M | - |
| 2023 | $-13.38 | $7.16M | $-61.23M | -854.8% |
| 2024 | $-6.69 | $28.52M | $-40.18M | -140.9% |
| 2025 | $-0.55 | $72.3M | $-6.12M | -8.5% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.01 | $-7.49 – $3.47 | $62.95M | $62.95M – $62.95M | 2 |
| 2027 | $-3.22 | $-5.54 – $-0.90 | $75.5M | $75.5M – $75.5M | 2 |
| 2028 | $-1.82 | $-4.27 – $0.63 | $93.5M | $93.5M – $93.5M | 2 |
| 2029 | $-3.45 | $-3.45 – $-3.45 | $18.5M | $18.5M – $18.5M | 1 |
| 2030 | $-0.65 | $-0.65 – $-0.65 | $186.8M | $186.8M – $186.8M | 1 |
